莫沙必利联合胰激肽原酶治疗糖尿病神经源性膀胱50例疗效及安全性分析

Clinical Efficacy and Safety Analysis of Mosapride Combined with Pancreatic Kallikrein in Treating Diabetic Neurogenic Bladder in 50 Cases

目的观察莫沙必利联合胰激肽原酶治疗糖尿病神经源性膀胱(DNB)的临床疗效及安全性。方法将2007年2月至2013年2月100例确诊患者按照平行分组的方法随机均分为对照组与观察组,各50例。两组患者均接受降糖、降压、调脂等基础治疗,观察组在此基础上应用莫沙必利联合胰激肽原酶进行治疗,比较两组疗效、治疗前后患者的膀胱残余尿量、生存质量、不良反应及随访情况等。结果对照组临床治疗总有效率为68.00%,明显低于观察组的94.00%(P<0.01);两组治疗后膀胱残余尿量均较治疗前出现明显降低(P<0.05或P<0.01),且观察组治疗后膀胱残余尿量与对照组治疗后相比,差异具有统计学意义(P<0.05);两组治疗后生存质量总评分较治疗前均明显升高(P<0.05或P<0.01),且观察组治疗后生存质量与对照组治疗后相比,差异具有统计学意义(P<0.05);两组治疗期间,均无不良反应发生;两组均获随访12个月,观察组复发率明显小于对照组(P<0.01)。结论莫沙必利联合胰激肽原酶治疗糖尿病神经源性膀胱,效果显著,值得临床推广。

Objective To investigate the clinical efficacy and safety of mosapride combined with pancreatic kallikrein in treating dia-betic neurogenic bladder(DNB). Methods 100 cases of diagnosed DNB in our hospital from February 2007 to February 2013 were randomly divided into the control group and the observation group according to the parallel grouping method,50 cases in each group. All patients received the basic treatment of reducing blood glucose,reducing blood pressure and regulating blood lipids. On this basis the observation group was given the treatment of mosapride combined with pancreatic kallikrein. The clinical efficacy,bladder residual urine amount before and after treatment,quality of life,adverse reactions and following - up,etc. were compared between the to groups. Results The total effective rate in the control group was 68. 00% ,which was significantly lower than 94. 00% in the obser-vation group( P < 0. 01);the bladder residual urine volume after treatment in the two groups was significantly reduced( P < 0. 05, P < 0. 01),moreover there was a statistical difference in the bladder residual urine volume between the two groups( P < 0. 05);ac-cording to the evaluation criteria of quality of life(QOL),the QOL scores after treatment in the two groups were significantly increased compared with before treatment( P < 0. 05,P < 0. 01),moreover there was a statistical difference in the QOL scores after treatment between the two groups ( P < 0. 05);no adverse reactions during the therapeutical process occurred in the two groups;the two groups were followed up for 12 months,the recurrence rate of the observation group was significantly lower than that of the control group( P < 0. 01). Conclusion Mosapride combined with pancreatic kallikrein has a significant effect in the treatment of DNB and is worthy to be promoted in clinic.